Welcome to our dedicated page for Autonomix Medical news (Ticker: AMIX), a resource for investors and traders seeking the latest updates and insights on Autonomix Medical stock.
Autonomix Medical, Inc. develops precision nerve-targeted medical device technology for diagnosing and treating diseases involving the nervous system. The company’s platform includes a catheter-based microchip sensing array intended to detect and differentiate neural signals and support transvascular approaches to peripheral nerve identification and treatment.
Recurring AMIX news centers on clinical and scientific updates for transvascular radiofrequency energy-based ablation, including pain mitigation research in pancreatic adenocarcinoma and peripheral nerve modulation. Company announcements also cover medical and interventional conference presentations, abstract selections, publication strategy, corporate presentations, and the clinical validation process for its minimally invasive nerve-targeted platform.
Autonomix Medical (NASDAQ:AMIX), a medical device company specializing in precision nerve-targeted treatments, has announced its participation in an upcoming virtual investor webinar. The event will be hosted by Ladenburg Thalmann on Thursday, August 21, 2025, at 1:00 PM ET.
The webinar will feature Brad Hauser, President and CEO of Autonomix, in a discussion moderated by Jeffrey S. Cohen, Managing Director and Director of Equity Research at Ladenburg Thalmann. The event will include a Q&A session, with participants able to pre-submit questions via email.
Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in precision nerve-targeted treatments, will participate in the upcoming Webull Financial Corporate Connect Webinar Series focused on Biotech/MedTech companies.
The virtual presentation will be delivered by Brad Hauser, President and CEO, on Thursday, August 21, 2025, at 2:20 PM ET. The event is part of a broader virtual conference taking place from August 19-21, 2025.
Autonomix Medical (NASDAQ: AMIX) has completed the final design review of its groundbreaking intravascular nerve sensing catheter, marking a significant milestone toward U.S. clinical trials. The device, featuring a proprietary microchip-based sensing antenna array, is the first of its kind capable of detecting and differentiating nerve signals in real-time from within blood vessels.
The technology enables a novel "sense, treat and verify" approach, allowing physicians to detect nerve activity, guide energy delivery precisely, and confirm treatment efficacy during procedures. The company is preparing to submit an Investigational Device Exemption (IDE) to commence clinical trials, initially focusing on treating pancreatic cancer pain, with potential applications across multiple therapeutic areas including cardiology, pain management, and pulmonary disorders.
Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in nervous system disease diagnosis and treatment technologies, announced its participation in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference.
During the conference, CEO Brad Hauser shared insights about his career journey, his commitment to Autonomix, and his enthusiasm for the company's innovative technology. The presentation is now available for viewing on both the Virtual Investor website and the Events page in the Investors section of autonomix.com.
Autonomix Medical (NASDAQ: AMIX), a medical device company focused on precision nerve-targeted treatments, has secured $2.5 million in gross proceeds through warrant exercises. The company entered agreements with certain warrant holders to exercise warrants for 1,477,596 shares at a reduced price of $1.723 per share.
In exchange for the immediate exercise, Autonomix will issue new unregistered warrants for an equivalent number of shares, exercisable at $1.723 per share with a five-and-a-half-year term. Some holders opted to prepay $1.722 of the exercise price, receiving amended warrants with a $0.001 exercise price. The transaction is expected to close around July 23, 2025.
Autonomix Medical (NASDAQ: AMIX) has been granted U.S. Patent No. 12,295,646 for its "Smart Torquer" device, strengthening its intellectual property portfolio in nerve-sensing and modulation technology. The patent covers a device designed to enhance the manipulation of intravascular devices during minimally invasive procedures while enabling data communication.
The company's technology platform features a catheter-based microchip sensing array antenna that can detect and differentiate neural signals with enhanced sensitivity, followed by proprietary RF ablation for targeted nerve treatment. With over 80 issued patents and 40 pending applications, Autonomix is positioning itself in a multi-billion-dollar market opportunity across cardiovascular, renal, and other high-burden diseases.
Autonomix Medical (NASDAQ: AMIX), a medical device company focused on precision nerve-targeted treatments, has released a new CEO Corner segment featuring CEO Brad Hauser. The segment, now available on the company's website, discusses details about the company's recently announced planned follow-on market expansion study phase (PoC 2) of its proof-of-concept trial.
Autonomix Medical (NASDAQ:AMIX) has announced the enrollment and treatment of its first patient in the follow-on phase of its proof-of-concept human clinical trial (PoC 2). This expansion follows positive results from the initial PoC 1 study in patients with severe pancreatic cancer pain.
The PoC 2 phase aims to double the potential addressable market by evaluating the company's nerve ablation technology in additional visceral cancers that signal pain through the Celiac Plexus, as well as earlier stage pancreatic cancers with moderate to severe pain. The technology involves delivering transvascular energy to ablate problematic nerves for pain mitigation.
The company's platform technology has potential applications across multiple indications, including cardiology, hypertension, and chronic pain management. The current PoC 2 phase specifically focuses on interventional cancer pain management applications in areas such as pancreatic, gall bladder, liver, and bile duct cancers, with possibilities for further expansion in oncology and gastroenterology sectors.
Autonomix Medical (NASDAQ: AMIX) has been granted U.S. Patent No. 12,279,889 B2 for its innovative catheter-based platform technology. The patent covers advanced systems for locating, monitoring, and mapping electrophysiological signals during neuromodulation procedures.
The technology features a catheter-based microchip sensing array antenna designed to detect neural signals with enhanced sensitivity, followed by proprietary RF ablation for targeted nerve treatment. Key applications include chronic pain management, hypertension treatment, and cardiac modulation. The company plans to submit an IDE and begin U.S. clinical trials in 2025 for pancreatic cancer pain treatment.